Key Takeaway
Wegovy (semaglutide 2.4 mg) remains one of the most effective FDA-approved weight loss medications available, producing average body weight reductions...
Wegovy (semaglutide 2.4 mg) remains one of the most effective FDA-approved weight loss medications available, producing average body weight reductions of 15 to 17% in clinical trials. But it isn't the only option. Tirzepatide, liraglutide, compounded semaglutide, and other alternatives each offer distinct advantages depending on your health profile, budget, and goals.
Key Takeaways
- Wegovy (semaglutide 2.4 mg) produces average weight loss of 14.9 to 16.9% of body weight in the STEP trial program.
- Zepbound (tirzepatide) is a dual GLP-1/GIP agonist that showed up to 22.5% weight[1] loss in the SURMOUNT-1 trial[1], making it the most potent option currently available.
- Saxenda (liraglutide) is an older GLP-1 option with more modest results (about 8% weight loss) but a longer safety track record.
- Compounded semaglutide is prepared by licensed compounding pharmacies and is not FDA-approved as a finished drug product; formulation, pharmacy quality, dosing, and individual response can differ from brand-name semaglutide products.
- Ozempic contains the same drug as Wegovy (semaglutide) but at a lower dose and is FDA-approved for diabetes, not weight management.
- The best choice depends on your medical history, weight loss goals, side effect tolerance, insurance coverage, and budget.
How Your Options in 2026
The weight loss medication field has expanded quickly over the past few years. If you're exploring Wegovy, you have likely seen headlines about other drugs claiming bigger numbers or lower prices. We're going to walk through each alternative honestly, with real clinical data, so you can have an informed conversation with your provider. For a complete cost breakdown, see our affordable GLP-1 options. For a complete cost breakdown, see our cheapest semaglutide options.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
A quick note before we begin: there's no single "best" medication. The best option is the one that fits your health needs, produces results you can sustain, and works within your financial situation. Anyone claiming one drug is universally superior is oversimplifying.
FormBlends
FormBlends is a U.S. telehealth platform that prescribes compounded semaglutide and tirzepatide. Patients complete an online intake, a licensed provider reviews eligibility, and medication ships from a 503A compounding pharmacy. Monthly pricing starts at $199. Start your intake.
How GLP-1 Medications Work
All GLP-1 based weight loss medications share a core mechanism. They mimic the incretin hormone GLP-1 (glucagon-like peptide-1), which your gut naturally produces after eating. This hormone tells your brain you're satisfied, slows the speed at which food leaves your stomach, and helps your pancreas regulate blood sugar.
Where medications differ is in which receptors they target (some hit GIP or glucagon in addition to GLP-1), how long they stay active in the body, and their dosing schedules. These differences translate into meaningful variations in weight loss results, side effect profiles, and cost. Understanding those distinctions is the key to making the right choice for your situation.
Wegovy: The Baseline
Before we compare alternatives, let us establish what Wegovy brings to the table.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Wegovy is semaglutide at a 2.4 mg weekly dose, FDA-approved specifically for chronic weight management. It works as a GLP-1 receptor agonist, mimicking the gut hormone that tells your brain you're full, slows gastric emptying, and improves insulin sensitivity.
Clinical Results
| Trial | Duration | Average Weight Loss (Wegovy) | Average Weight Loss (Placebo) |
|---|---|---|---|
| STEP 1[2] | 68 weeks | 14.9% | 2.4% |
| STEP 2 (with type 2 diabetes) | 68 weeks | 9.6% | 3.4% |
| STEP 3 (intensive behavioral therapy) | 68 weeks | 16.0% | 5.7% |
| STEP 5 (2-year data) | 104 weeks | 15.2% | 2.6% |
Cardiovascular Benefits
Wegovy has a significant advantage that no other weight loss medication currently matches: proven cardiovascular risk reduction. The SELECT trial[6] showed that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20%[6] in overweight and obese patients with established heart disease . This led to an expanded FDA indication for cardiovascular risk reduction.
Cost
Without insurance, Wegovy runs approximately $1,300 to $1,500 per month $1,300-$1,400/mo (brand). Insurance coverage varies widely. Many plans cover it for diabetes-related indications but exclude weight management.
Side Effects
The most common side effects of Wegovy are gastrointestinal: nausea (44% of patients), diarrhea (30%), vomiting (24%), and constipation (24%). These are most pronounced during the dose escalation period and tend to improve over time. The gradual 16-week escalation schedule is specifically designed to minimize these effects.
Serious side effects are rare but include pancreatitis, gallbladder disease, and a boxed warning about thyroid C-cell tumors observed in animal studies. Patients with a personal or family history of medullary thyroid carcinoma shouldn't use Wegovy.
Who Wegovy Works Best For
Wegovy is a strong all-around choice for most patients. It's particularly well-suited for patients with cardiovascular risk factors (due to the SELECT trial data), patients who want a well-studied medication with extensive published research, and patients who prefer the convenience of a pre-filled pen device. It also pairs well with structured lifestyle programs. In the STEP 3 trial, patients who combined Wegovy with intensive behavioral therapy lost an average of 16% of body weight, the highest result in the STEP program.
Wegovy vs. Zepbound (Tirzepatide)
Zepbound is probably the closest head-to-head competitor to Wegovy. It contains tirzepatide, a dual GLP-1 and GIP receptor agonist made by Eli Lilly, FDA-approved for chronic weight management.
How They Differ
| Factor | Wegovy (semaglutide) | Zepbound (tirzepatide) |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Average weight loss | 14.9 to 16.9% | Up to 22.5% |
| Dosing | Once weekly injection | Once weekly injection |
| Max dose | 2.4 mg | 15 mg |
| CV risk reduction data | Yes (SELECT trial) | Pending (SURPASS-CVOT ongoing) |
| Monthly cost (without insurance) | $1,300 to $1,500 | $1,000 to $1,200 |
| Nausea rate | ~44% | ~33% |
$1,000-$1,200/mo (brand)
Key Points
Tirzepatide (Zepbound) produces greater average weight loss than Wegovy and may cause slightly less nausea. But Wegovy has a longer track record, proven cardiovascular benefits, and more published long-term safety data. If raw weight loss numbers are your top priority, Zepbound has the edge. If heart health is a major concern, or you prefer a drug with more years of real-world data, Wegovy is the stronger choice.
Wegovy vs. Ozempic
This comparison confuses a lot of people because Wegovy and Ozempic contain the exact same drug: semaglutide. The differences are regulatory, not chemical.
| Factor | Wegovy | Ozempic |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA indication | Chronic weight management | Type 2 diabetes |
| Max dose | 2.4 mg/week | 2 mg/week |
| Dose escalation schedule | 5 steps over 16 weeks | 3 to 4 steps |
| Insurance for weight loss | Sometimes covered | Often not covered for weight loss (off-label) |
| Monthly cost | $1,300 to $1,500 | $900 to $1,200 |
$900-$1,000/mo (brand)
Many providers prescribe Ozempic off-label for weight loss because insurance may cover it more readily for patients with type 2 diabetes or prediabetes. The lower maximum dose (2 mg vs. 2.4 mg) means slightly less weight loss on average, but the difference is modest. If you have diabetes or prediabetes alongside obesity, Ozempic may make more practical and financial sense.
Wegovy vs. Compounded Semaglutide
Compounded semaglutide is the same active molecule prepared by compounding pharmacies rather than by Novo Nordisk (the manufacturer of Wegovy and Ozempic). This option has become increasingly popular due to its dramatically lower price.
| Factor | Wegovy (brand) | Compounded Semaglutide |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA-approved product | Yes | No (compounded under FDA guidance) |
| Monthly cost | $1,300 to $1,500 | $200 to $500 |
| Insurance coverage | Varies | Typically not covered |
| Delivery device | Pre-filled pen | Vial and syringe (usually) |
| Physician supervision | Required | Required |
From $299
The Key Consideration
Quality and safety depend entirely on the compounding pharmacy and the physician program overseeing your care. Reputable programs like FormBlends source from licensed, inspected compounding pharmacies and provide the same physician oversight, dose escalation protocols, and monitoring you would get with brand-name Wegovy. The medication, the molecule, is identical. The difference is price and packaging.
For patients who can't afford Wegovy out of pocket and don't have insurance coverage, compounded semaglutide is often the most practical path to treatment.
Wegovy vs. Mounjaro (Tirzepatide for Diabetes)
Mounjaro is the diabetes-approved version of tirzepatide (Zepbound is the weight loss version). The relationship mirrors Ozempic and Wegovy: same drug, different FDA indication.
Mounjaro is sometimes prescribed off-label for weight loss, particularly for patients who also have type 2 diabetes or insulin resistance. If your provider prescribes Mounjaro for diabetes and you also lose weight, that's an on-label use with a welcome side benefit.
The clinical data for tirzepatide weight loss (from the SURMOUNT trials) applies equally to both brand names since the active ingredient is in the same class.
Practical Considerations
The main reason patients end up on Mounjaro instead of Zepbound is insurance. Many health plans cover tirzepatide for type 2 diabetes but exclude or restrict it for weight management alone. If you have diabetes or prediabetes and also need to lose weight, Mounjaro may be the more financially accessible path to the same medication. Monthly cost without insurance is approximately $1,000 to $1,200, similar to Zepbound $1,000-$1,200/mo (brand).
Mounjaro uses the same dose escalation approach as Zepbound, starting at 2.5 mg and increasing in steps up to 15 mg. The dose titration schedule is slightly different from Wegovy's, with increases every 4 weeks. Your provider will determine the right pace based on your tolerance and response.
Wegovy vs. Saxenda (Liraglutide)
Saxenda was the first GLP-1 receptor agonist approved for weight management, receiving FDA approval in 2014. It contains liraglutide at a 3 mg daily dose.
| Factor | Wegovy (semaglutide) | Saxenda (liraglutide) |
|---|---|---|
| Dosing frequency | Once weekly | Once daily |
| Average weight loss | 14.9 to 16.9% | About 8% |
| Side effect profile | Similar GI effects | Similar GI effects |
| Monthly cost | $1,300 to $1,500 | $1,300 to $1,500 |
| Convenience | 1 injection per week | 1 injection per day |
| Long-term safety data | Published through 2 years | Published through 3+ years |
Contact provider for current pricing
When Saxenda Makes Sense
Saxenda produces less weight loss, costs about the same, and requires daily injection. So why would anyone choose it? A few scenarios:
- Patients who tried Wegovy (or semaglutide) and couldn't tolerate the side effects may do better on liraglutide.
- Some patients prefer daily dosing because it feels more routine and the lower per-dose amount may cause fewer GI issues.
- Insurance may cover Saxenda when it doesn't cover Wegovy.
- Saxenda has a slightly longer real-world safety record.
For most patients, however, Wegovy is the stronger choice in this matchup due to superior efficacy and the convenience of weekly dosing.
Wegovy vs. Emerging Medications
Retatrutide
Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors. In Phase 2 trials, it produced weight loss of up to 24.2% over 48 weeks, which could surpass even tirzepatide . Phase 3 trials are underway. If approved, retatrutide[7] could become the new standard, but it isn't available outside of clinical trials as of early 2026.
Oral Semaglutide for Weight Loss
Novo Nordisk is developing a high-dose oral semaglutide (25 to 50 mg daily tablet) for weight management. Early data suggests weight loss comparable to injectable Wegovy. An oral option would eliminate the injection barrier that prevents some patients from starting treatment. This is still in late-stage clinical trials.
CagriSema
CagriSema combines semaglutide with cagrilintide (an amylin analog). Early data from the REDEFINE trials showed weight loss of approximately 22 to 24%, potentially matching or exceeding tirzepatide. This combination approach targets multiple appetite-regulating pathways simultaneously.
Non-GLP-1 Alternatives
Not every patient is a candidate for GLP-1 medications, and some patients prefer non-injectable options. Here are the main alternatives outside the GLP-1 class:
| Medication | How It Works | Average Weight Loss | Notes |
|---|---|---|---|
| Phentermine-topiramate (Qsymia) | Appetite suppressant + anti-seizure drug | 7 to 10% | Oral, potential cardiovascular side effects |
| Naltrexone-bupropion (Contrave) | Targets reward and appetite centers | 5 to 8% | Oral, helpful for emotional eating patterns |
| Orlistat (Alli/Xenical) | Blocks fat absorption | 3 to 5% | Over-the-counter available, GI side effects |
| Bariatric surgery | Surgical modification of stomach/intestines | 25 to 35% | Permanent, significant risks, highest efficacy |
None of these non-GLP-1 medications match the efficacy of Wegovy or Zepbound. But they remain viable options for patients with contraindications to GLP-1 medications or those who prefer oral medications with a longer safety history.
A Note on Bariatric Surgery
Bariatric surgery (gastric bypass, gastric sleeve) remains the most effective intervention for severe obesity, producing 25 to 35% weight loss that's generally maintained long-term. But it's an irreversible surgical procedure with meaningful risks, including nutritional deficiencies, dumping syndrome, and surgical complications. Recovery takes weeks, and lifelong dietary modifications are required.
GLP-1 medications like Wegovy have narrowed the efficacy gap between medication and surgery significantly. For many patients who would have been recommended for surgery in the past, GLP-1 treatment now offers a less invasive alternative with results that approach surgical outcomes. But bariatric surgery may still be the best option for patients with BMI over 40, or those who haven't responded adequately to medication.
Combination Approaches
Some providers combine non-GLP-1 medications with GLP-1 treatment. For example, adding phentermine to semaglutide may help patients push past a weight loss plateau. These combinations are prescribed off-label and should only be used under close physician supervision. If your weight loss has stalled on Wegovy alone, discuss combination strategies with your provider rather than self-medicating.
How to Choose: Decision Framework
Here is a practical framework for thinking through your options:
- If you want the highest possible weight loss and can afford it: Zepbound (tirzepatide) has the strongest efficacy data.
- If cardiovascular health is a major concern: Wegovy (semaglutide) is the only weight loss medication with proven heart-protective benefits.
- If cost is your primary barrier: Compounded semaglutide through a physician-supervised program like FormBlends offers the best value.
- If you have type 2 diabetes: Ozempic or Mounjaro may provide insurance coverage advantages and dual benefits.
- If you tried semaglutide and couldn't tolerate it: Tirzepatide (which may cause less nausea) or liraglutide (lower dose, daily) are worth discussing with your provider.
- If you refuse injections: Oral options like Contrave or Qsymia are available now, with oral semaglutide on the horizon.
The most important step is talking to a qualified provider who can evaluate your full medical picture. Weight loss medication isn't one-size-fits-all.
Frequently Asked Questions
Is Wegovy better than Ozempic for weight loss?
Wegovy and Ozempic contain the same drug (semaglutide). Wegovy goes up to 2.4 mg per week while Ozempic tops out at 2 mg. The higher dose means slightly more weight loss on average. Wegovy also has the FDA weight management indication, while Ozempic is technically off-label for weight loss. Clinically, the difference in results is modest.
Is Zepbound more effective than Wegovy?
In head-to-head data, tirzepatide (Zepbound) produces greater average weight loss than semaglutide (Wegovy). The SURMOUNT-1 trial showed up to 22.5% weight[1] loss with tirzepatide vs. 15 to 17% with semaglutide in the STEP trials. But individual results vary, and Wegovy has advantages in cardiovascular risk reduction and length of safety data.
Is compounded semaglutide as safe as Wegovy?
When sourced from a licensed, inspected compounding pharmacy and prescribed through a physician-supervised program, compounded semaglutide carries a comparable safety profile. The active ingredient is the same. The key is ensuring you work with a reputable provider, not an unregulated online source.
Can I switch from Wegovy to another medication?
Yes, switching is common and generally straightforward. Your provider will determine an appropriate starting dose on the new medication based on what you were taking. Switching from Wegovy to tirzepatide is one of the most common transitions, usually when patients want to try for greater weight loss.
Why is Wegovy so expensive?
Wegovy is a brand-name biologic produced by Novo Nordisk. The price reflects R&D costs, lack of generic competition (though compounded options exist), and high demand. Insurance coverage is improving but remains inconsistent. Compounded semaglutide and manufacturer savings programs can significantly reduce out-of-pocket costs.
Which weight loss medication has the fewest side effects?
All GLP-1 medications cause similar GI side effects (nausea, diarrhea, constipation). Some data suggests tirzepatide may cause slightly less nausea than semaglutide. Liraglutide (Saxenda) may be gentler due to its daily dosing pattern. Side effect experience is highly individual, and what bothers one patient may not affect another at all.
Should I choose a medication based on clinical trial data alone?
Clinical trial averages are helpful benchmarks, but they don't predict your individual response. Factors like your metabolic profile, medication tolerance, lifestyle, budget, and insurance all matter. A conversation with a provider who knows your full health picture is always the best starting point.
How do I know if Wegovy is working?
Most patients notice reduced appetite and smaller portions within the first 2 to 4 weeks, even at the starting dose. Measurable weight loss typically becomes apparent by weeks 8 to 12. If you have been on the maintenance dose (2.4 mg) for 3 to 6 months without losing at least 5% of your starting body weight, talk to your provider about adjusting your approach or considering an alternative medication.
Can I take Wegovy and another weight loss medication at the same time?
Combination therapy is sometimes used off-label, but it should only be done under direct physician supervision. Don't add medications on your own. Your provider can assess whether a combination approach is safe and appropriate based on your specific health profile.
What happens if I switch from Wegovy to a different GLP-1 medication?
Switching between GLP-1 medications is generally smooth. Your provider will determine a starting dose on the new medication that corresponds roughly to what you were taking. You typically don't need to go through the full dose escalation again, though you may start at a moderate dose for a week or two to gauge tolerance. Most patients don't experience a significant gap in weight management during the transition.
Medical References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. [PubMed | ClinicalTrials.gov | DOI]
Find the Right Medication with Expert Guidance
Choosing between Wegovy and its alternatives can feel overwhelming with so many options and so much conflicting information. At FormBlends, our physicians evaluate your full health history, discuss your goals and budget, and recommend the option that gives you the best chance of lasting success. Whether that's brand-name Wegovy, compounded semaglutide, or another path entirely, we help you make the decision with confidence.